Bioscience

ImmuneRegen BioSciences

January 27, 2010

By Flinn Foundation

[Source: PR Canada] – ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), ends 2009 with a significantly deeper understanding of the mechanisms underlying the demonstrated immunostimulatory activity of its development candidate Homspera®, and additional partners and advisory members who strengthen the Company’s efforts to bring Homspera into human testing.

Relationships forged over the past 3 calendar quarters have included those with investigators at the University of Rochester and the University of Pittsburgh, and the Company has entered into a joint licensing agreement with the latter in the area of cancer vaccine adjuvants. Both investigators have subsequently joined the Company’s Advisory Board and continue to support the Company’s research and grant submission activities.

For more information: ImmuneRegen BioSciences® Summarizes Previous 9 Months of Advances as Homspera Development Continues